phrykt

Lifecore Biomedical, Inc. \De\ (LFCR): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of LFCR were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lifecore Biomedical, Inc. \De\

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LFCR

99 funds and institutions reported LFCR shares worth $134M at the end of Q2 2026, about 68% of the company. The largest holder is Wynnefield Capital Inc with 12.5%.

Funds and institutions (13F) 68%Everyone else 32%

10 largest owners, by share of the company

Wynnefield Capital Inc12.5%
Legion Partners Asset Management, LLC11.9%
Greenhaven Road Investment Management, L.P.8.5%
325 Capital LLC7.7%
BlackRock, Inc.5.4%
Vanguard Capital Management LLC3.4%
Geode Capital Management, LLC2.3%
Morgan Stanley2.1%
State Street Corp1.8%
Quinn Opportunity Partners LLC1.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Wynnefield Capital Inc4.70M12.55%$24.7MNo change
Legion Partners Asset Management, LLC4.46M11.91%$23.4MNo change
Greenhaven Road Investment Management, L.P.3.19M8.51%$16.8M-10%
325 Capital LLC2.90M7.73%$15.2M+34%
BlackRock, Inc.2.01M5.37%$10.6M+7%
Vanguard Capital Management LLC1.29M3.44%$6.8M-0%
Geode Capital Management, LLC855,5002.28%$4.5M+5%
Morgan Stanley769,3602.05%$4M+1%
State Street Corp668,0311.78%$3.5M+4%
Quinn Opportunity Partners LLC453,4951.21%$2.4MNo change
DCF Advisers, LLC424,5001.13%$2.2MNo change
Wittenberg Investment Management, Inc.314,0150.84%$1.6M+4%
Northern Trust Corp253,8170.68%$1.3M+11%
Vanguard Fiduciary Trust Co239,9240.64%$1.3M+1%
LPL Financial LLC207,3000.55%$1.1M-0%
Vanguard Portfolio Management LLC189,0730.50%$993K+15%
Marshall Wace, LLP177,4710.47%$932K+204%
Tocqueville Asset Management L.P.151,7000.40%$796KNo change
Millennium Management LLC133,3050.36%$700K-15%
Goldman Sachs Group Inc124,9400.33%$656K-26%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No LFCR insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LFCR short interest

Low short interest. 4.5% of LFCR shares are sold short: about 1 share in 22. Over the last 12 reports the number of shares short went down 33%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.72M LFCR shares were sold short, 4.5% of the shares outstanding, down 4.5% from the report before. At the average daily volume of 489,149 shares, buying them all back would take about 3.5 trading days (days to cover).

Shares short, % of all shares

4.54%May 15Oct 307.43%

Days to cover

3.5May 15Oct 3026.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.72M4.54%-4%489,1493.5
Oct 15, 20261.80M4.76%-27%652,0622.8
Sep 30, 20262.48M6.54%-7%605,5554.1
Sep 15, 20262.67M7.05%+10%167,49515.9
Aug 31, 20262.42M6.40%+0%104,47723.2
Aug 14, 20262.42M6.38%-7%139,16617.4
Jul 31, 20262.61M6.88%+5%142,46718.3
Jul 15, 20262.48M6.62%+4%168,84414.7
Jun 30, 20262.38M6.36%+0%304,0067.8
Jun 15, 20262.37M6.34%+1%193,08212.3
May 29, 20262.35M6.28%-8%184,76012.7
May 15, 20262.56M6.84%-5%190,93713.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lifecore Biomedical, Inc. \De\ company events

Lifecore Biomedical, Inc. \De\ filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementAs previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. providing for the merger of Merger Sub with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. Filing
  2. Nov 4, 2026ResultsReleased financial results. Filing
  3. Oct 20, 2026AnnouncementAs previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors of the Company established November 4, 2026, as the record date for a special meeting of… Filing
  4. Sep 29, 2026AgreementLifecore Biomedical, LLC, a subsidiary of Lifecore Biomedical, Inc., entered into an Amendment No. 3 to Amended and Restated Contract Manufacturing Agreement with Alcon Research, LLC that is effective November 1, 2026. Filing
  5. Sep 28, 2026AgreementLifecore Biomedical, Inc. entered into an Agreement and Plan of Merger by and among the Company, Lifecore Inc., a Delaware corporation, and Hazel Merger Sub, Inc., a Delaware corporation and a direct wholly owned Subsidiary of Parent. Filing
  6. Aug 5, 2026ResultsReleased financial results. Filing
  7. Jul 2, 2026AnnouncementShared information with investors. Filing
  8. Jun 5, 2026LeadershipLifecore Biomedical, Inc. held its 2026 annual meeting of stockholders. Filing
  9. May 6, 2026ResultsReleased financial results. Filing
  10. Mar 16, 2026ResultsReleased financial results. Filing
  11. Mar 5, 2026VoteSet dates for shareholder nominations. Filing
  12. Jan 16, 2026LeadershipThe Compensation Committee of the Board of Directors of Lifecore Biomedical, Inc. approved and adopted the Lifecore Biomedical, Inc. Incentive Bonus Plan effective January 14, 2026 for bonus awards granted on or after the Effective Date. Filing
  13. Nov 17, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lifecore Biomedical, Inc. \De\ financials

Famous investors that hold LFCR

3 of the 50 well-known investors we track reported holding LFCR in their latest 13F filing. The largest position is Ken Griffin's, worth $1.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026285,190$1.9M0.0%+188%
Jim Simons · Renaissance TechnologiesQ3 2026163,000$1.1M0.0%+55%
Israel Englander · Millennium ManagementQ3 202662,555$412K0.0%-53%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LFCR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Greenhaven Road Investment Management, L.P.13G/A7.6%
Nov 16, 2026Greenhaven Road Investment Management, L.P.13G/A7.6%

Questions about Lifecore Biomedical, Inc. \De\ (LFCR) stock

Who owns the most LFCR stock?

The largest reported owner of Lifecore Biomedical, Inc. \De\ (LFCR) is Wynnefield Capital Inc, with 12.5% of the company. In total, 99 funds and institutions reported holding LFCR at the end of Q2 2026, together about 68% of the shares. See the largest owners.

Are LFCR insiders buying or selling?

No LFCR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in LFCR?

As of Oct 30, 2026, 1.72M LFCR shares were sold short, 4.5% of the shares outstanding, down 4.5% from the report before. At the average daily volume of 489,149 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.

Which famous investors hold LFCR?

3 of the 50 well-known investors we track reported LFCR in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $1.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.